PRESS-RELEASE ·Filed Mar 24, 2026
Press release · Earnings
Actionable Insight • Neutral
Monitor for upcoming data readouts from later-stage cohorts or the MAD (Multiple Ascending Dose) portion upcoming.
Final — all horizons settled through T+60d
ABSI ▲ +186.99% at T+60d
NEUTRAL call +186.99% · α vs SPY +173.53% · entry $2.92 → $8.38
T+1d
-1.37%
call -1.37% · α +0.40%
$2.88
settled 7mo ago
T+5d
+7.88%
call +7.88% · α +8.12%
$3.15
settled 7mo ago
T+20d
+35.96%
call +35.96% · α +28.10%
$3.97
settled 6mo ago
T+60d
+186.99%
call +186.99% · α +173.53%
$8.38
settled 4mo ago
Price Chart
Loading chart...
Executive Summary
Absci Corporation announced the successful dosing of the first three cohorts in the SAD portion of its ABS-201™ HEADLINE trial, reporting that the drug candidate was well-tolerated with favorable emerging safety data. This represents early-stage clinical progress for the company's lead program, though no financial or efficacy results were disclosed.
Key Facts
- First three cohorts in the SAD (Single Ascending Dose) portion of the ABS-201™ HEADLINE trial have been successfully dosed.
- ABS-201™ was well-tolerated with favorable emerging safety data.
- No financial results, efficacy data, or pharmacokinetic details were provided.
- Trial remains ongoing; next steps not specified in the release.
Financial Impact
Not specified
Market Snapshot
Exchange
Nasdaq
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3261722 |
10 reports for ABSI
100% Hit rate @ T+5 Went positive at some point 4 of 4 best @ T+5▲ +10.27%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 10w ago | Institutional Cluster | $9.50 $9.99 | ▲ +5.16% | ▲ +5.60% | $10.65 (+12.11%) |
Jul 6, 2026 16w ago | Insider Buy | $11.33 $10.23 | ▼ −9.71% | ▼ −10.26% | $10.65 (−6.00%) |
Jun 24, 2026 17w ago | 8-K | $10.21 $11.11 | ▲ +8.81% | ▲ +7.25% | $10.65 (+4.31%) |
Jun 24, 2026 17w ago | 424B5 | $10.21 $11.11 | ▲ +8.81% | ▲ +7.25% | $10.65 (+4.31%) |
Jun 24, 2026 17w ago | Press Release | $10.08 $11.11 | ▲ +10.27% | ▲ +8.57% | $10.65 (+5.71%) |
Jun 24, 2026 17w ago | 8-K | $10.08 $11.11 | ▲ +10.27% | ▲ +8.57% | $10.65 (+5.71%) |
Jun 24, 2026 17w ago | Press Release | $10.08 $11.11 | ▲ +10.27% | ▲ +8.57% | $10.65 (+5.71%) |
Apr 23, 2026 26w ago | Press Release | $3.94 $4.98 | ▲ +26.27% | ▲ +25.36% | $10.65 (+170.30%) |
Apr 22, 2026 26w ago | DEFA14A | $3.97 $4.71 | ▲ +18.64% | ▲ +17.16% | $10.65 (+168.26%) |
Mar 24, 2026 30w ago | Press Release | $2.92 $3.15 | ▲ +7.88% | ▲ +8.12% | $10.65 (+264.73%) |
Showing 10 of 10
US Market Status
Market Open — Closes in 1h 42m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers